Search
for
Sort by
Research 121–150 of 1000+
- Taxane-induced alopecia: A historical review of patients with ovarian or breast cancer treated with with paclitaxel, docetaxel or paclitaxel poliglumex
- Off-label prescriptions: patient safety first
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
- The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study
- Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
- Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab Paclitaxel
- Patient-reported outcomes following various incision techniques in breast reconstruction: an observational cohort study in China
- Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen
- Persistent radiation-induced alopecia in patients with central nervous system tumors and head and neck sarcomas.
- Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
- Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Incidence of alopecia in brain tumour patients treated with pencil scanning proton therapy and validation of existing NTCP models
- Care for alopecia during chemotherapy of cancer patients
- Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
- Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis
- Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients
- Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
- Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis
- CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
- Results of Ifosfamide Combination Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
- Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
- Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study
- First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.